KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Eli Lilly (LLY) Enterprise Value (2016 - 2026)

Eli Lilly filings provide 18 years of Enterprise Value readings, the most recent being -$5.3 billion for Q1 2026.

  • On a quarterly basis, Enterprise Value fell 68.29% to -$5.3 billion in Q1 2026 year-over-year; TTM through Mar 2026 was -$5.3 billion, a 68.29% decrease, with the full-year FY2025 number at -$7.3 billion, down 117.39% from a year prior.
  • Enterprise Value hit -$5.3 billion in Q1 2026 for Eli Lilly, up from -$7.3 billion in the prior quarter.
  • In the past five years, Enterprise Value ranged from a high of -$2.1 billion in Q4 2022 to a low of -$9.9 billion in Q3 2025.
  • Median Enterprise Value over the past 5 years was -$3.1 billion (2025), compared with a mean of -$3.7 billion.
  • Biggest five-year swings in Enterprise Value: soared 44.11% in 2022 and later tumbled 186.7% in 2025.
  • Eli Lilly's Enterprise Value stood at -$2.1 billion in 2022, then tumbled by 35.94% to -$2.8 billion in 2023, then dropped by 17.89% to -$3.3 billion in 2024, then crashed by 117.39% to -$7.3 billion in 2025, then rose by 27.33% to -$5.3 billion in 2026.
  • The last three reported values for Enterprise Value were -$5.3 billion (Q1 2026), -$7.3 billion (Q4 2025), and -$9.9 billion (Q3 2025) per Business Quant data.